Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nektar Therapeutics insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 2 insiders, $441.1K in total
- Insiders trading
- 2
- Net value
- −$441.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nektar Therapeutics, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Whitfield Roy A | Director | 16,417 | Sep 25, 2026 | 2 |
| Greer R Scott | Director | 22,239 | Sep 25, 2026 | 2 |
| Chess Robert | Director | 19,019 | Sep 25, 2026 | 2 |
| Brainard Diana | Director | 3,904 | Sep 25, 2026 | 2 |
| Ajer Jeffrey Robert | Director | 4,277 | Sep 25, 2026 | 2 |
| Zalevsky Jonathan | Chief R&D Officer | 9,570 | Aug 20, 2026 | 9 |
| Robin Howard W | President & CEO | 54,627 | Aug 20, 2026 | 7 |
| Wilson Mark Andrew | Chief Legal Officer | 21,585 | Nov 25, 2025 | 1 |
| Kroin David | 10% Owner | 18,344,000Indirect | May 13, 2024 | 0 |
| Deep Track Capital, LP | 10% Owner | 18,344,000Indirect | May 13, 2024 | 0 |
| Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | 18,344,000Indirect | May 13, 2024 | 0 |
| Curet Myriam | Director | 27,418 | Sep 20, 2023 | 0 |
| Thomsen Jillian B. | Chief Financial Officer | 313,497 | Feb 17, 2023 | 0 |
| Eastham Karin | Director | 23,233 | Sep 20, 2022 | 0 |
| Labrucherie Gil M | SVP, COO & CFO | 312,905 | May 17, 2022 | 0 |
| Northcott John | SVP & Chief Commercial Officer | 223,210 | May 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 (view filing)7:06 PM ET | Jun 30 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −5.68K | $70.00 | −$397.7K | −36.8%9.76K after | 10b5-1 |
| Aug 20, 2026 (view filing)7:03 PM ET | Aug 18 | 2 days | Robin Howard WPresident & CEO | SSale | −418 | $71.98 | −$30.1K | −0.8%54.6K after | |
| Aug 20, 2026 (view filing)7:05 PM ET | Aug 18 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −186 | $71.98 | −$13.4K | −1.9%9.57K after |